Patient Satisfaction Following Multidisciplinary Cancer Care Assessment in Day Hospital: A Prospective Observational Study.
NCT07560423
Behavior, Cancer
Martigues, Bouches du Rhone, France
View Trial DetailsNCT Number: NCT05989191
The aim of this study is to validate the EORTC PATSAT-C33 and EORTC OUT-PATSAT7 questionnaires scale structure in a large international field study.
This study is active but is not currently recruiting participants.
18 year and older
All sexes
Observational
Institut Curie, Paris, France
Patient satisfaction is now recognized as an important indicator of care quality. Measures of patient satisfaction with care can facilitate monitoring initiatives for care improvement over time. The EORTC Quality of Life Group has cross-culturally validated a stand-alone in-patient satisfaction with cancer care questionnaire, the IN-PATSAT32. Advances in cancer care delivery required further development of this questionnaire to assess patients' perceived quality of the care received in outpatient cancer care settings. Phase I to III of this process have been completed, resulting in the EORTC PATSAT-C33 satisfaction with cancer care core questionnaire to assess cancer care delivery as a whole and the complementary EORTC OUT-PATSAT7, a questionnaire for the specific outpatient care settings. These questionnaires concern all patients treated for their cancer, in the assessed service, regardless of the stage and type of cancer.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Patients regardless of cancer site or stage of disease (i.e. local, loco-regional, metastatic, in remission) will be invited to participate if they meet the following criteria:
a. For outpatients consulting in a chemotherapy day clinic/consultation for oral treatment, ambulatory radiotherapy or consultation for follow-up surveillance to check for signs of recurrence : i) between 3 to 6 cycles of chemotherapy or at least 2 cycles of other cancer treatment (e.g., biological oral therapy) or ii) between 2 to 6 weeks of radiotherapy or iii) within the 3rd to 24th month post-cancer treatment. b. For inpatients consulting on an oncology or a surgery ward at least 3 days of hospital stay
Exclusion criteria
Patients will be excluded if they are :
Time frame: At inclusion
Adequacy of confirmatory factor analyses estimates of EORTC PATSAT-C33 and EORTC OUT-PATSAT7 questionnaires
PATSAT-C33 scales:
PATSAT-C33 single items :
Time frame: At inclusion
Adequacy of confirmatory factor analyses estimates of EORTC PATSAT-C33 and EORTC OUT-PATSAT7 questionnaires
OUT-PATSAT7 scales:
OUT-PATSAT7 single item
Time frame: At inclusion
Adequacy of estimates of cross-cultural applicability and acceptability
Time frame: change between inclusion and week 2
Adequacy of estimates for Reliability including test-retest and internal consistency
Time frame: At inclusion
Adequacy of estimates of validity, including construct (known-group comparisons)
Time frame: At inclusion
Adequacy of estimates of convergent and divergent validity
Time frame: change between inclusion and year 1
Adequacy of estimates of responsiveness to change
Time frame: At inclusion
Adequacy of estimates of cross-cultural invariance of psychometric properties
Institut Curie
Other
An International Field Study for the Reliability and Validity of the EORTC PATSAT-C33 and the EORTC OUT-PATSAT7 Questionnaires
Acronym: PATSAT
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07560423
Behavior, Cancer
Martigues, Bouches du Rhone, France
View Trial DetailsNCT07387497
Anxiety, Anxiety Disorders
Malatya, Turkey (Türkiye)
View Trial DetailsNCT04843332
Behavior, Cancer
Stanford, California, United States
View Trial DetailsNCT06522503
Behavior, Cancer
Izmir, Menemen, Turkey (Türkiye)
View Trial Details